{"id":"1d98806a2264","type":"article","url":"https://hartvaat.nl/2026/02/27/obicetrapib-veelbelovende-cetp-remmer-voor-hoogrisicopatienten/","title":"Obicetrapib: veelbelovende CETP-remmer voor hoogrisicopatiënten","title_en":"Lipid-modifying efficacy and safety of obicetrapib in high-risk cardiovascular patients: A systematic review and meta-analysis.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["abelacimab","bempedoïnezuur","bloeddrukbehandeling","cetp-remmers","dyslipidemie","ezetimibe","familiaire-hypercholesterolemie-screening","hdl-cholesterol","lipide-aferese","lipidenverlaging","liraglutide","niet-statine-therapie","obicetrapib","pcsk9-remmers","pcsk9-remmers-nieuwe-generatie","pelacarsen","statines","trombocytenaggregatieremmers"],"journal":"Vascular diseases (Paris, France)","doi":"10.1016/j.vasdi.2026.02.004","source_url":"https://doi.org/10.1016/j.vasdi.2026.02.004","authors":["Abdul Mueez Alam Kayani","Muhammad Faiq Umar","Daniel Navarro-Martinez","Alan Garcia","Muhammad Affan Rashid","Ricky E Lemus-Zamora"],"significance":5,"published":"2026-03-08","source_date":"2026-02-27","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/hdl-functie-en-reverse-cholesterol/"],"congress":"","summary_en":"A systematic review and meta-analysis evaluated the lipid-modifying efficacy and safety of obicetrapib, a CETP inhibitor, in high-risk cardiovascular patients. The agent optimises lipid profiles by blocking cholesterol ester transfer between HDL and apoB-containing lipoproteins.","created":"2026-07-03T10:32:32Z","updated":"2026-07-03T13:31:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Een systematisch review en meta-analyse in Vascular Diseases beoordeelt de lipideverlagende werkzaamheid en veiligheid van obicetrapib, een nieuwe CETP-remmer. Bij hoogrisicopatiënten die ondanks behandeling hun LDL-C-streefwaarde niet halen, optimaliseert dit middel het lipidenprofiel door de uitwisseling van cholesterolesters tussen HDL en apoB-bevattende lipoproteïnen te blokkeren.","abstract_original":"INTRODUCTION: Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and mortality, particularly among high-risk patients. Despite the availability of multiple lipid lowering therapies, many patients fail to achieve the guideline recommended low-density lipoprotein cholesterol (LDL-C) targets. Obicetrapib, a cholesteryl ester transfer protein (CETP) inhibitor optimizes lipid profile by blocking the exchange of cholesterol esters from high-density lipoprotein cholesterol (HDL-C) to Apolipoprotein B (ApoB) containing lipoproteins. This study evaluates the efficacy and safety of obicetrapib as an adjunctive therapy in high-risk ASCVD patients. METHODS: Online databases were searched. Outcomes included percentage changes in LDL-C, HDL-C, non-HDL-C, total cholesterol, triglyceride, ApoB, lipoprotein (a) [Lp(a)] and risk of any adverse events (AE), AE leading to discontinuation, acute kidney injury (AKI), transaminase or creatine kinase (CK) elevation and hypertension. Risk ratio (RR) for categorical outcomes and mean difference (MD) for continuous outcomes were reported using 95% confidence intervals (CI). RESULTS: Three studies with 3088 patients (mean age 64 ± 11, 37% female) were selected. Obicetrapib significantly reduced LDL-C (-31.75%), non-HDL-C (-29.35%), triglyceride (-5.61%), Lp(a) (-35.67%), ApoB (-19.37%), and increased HDL-C (+125.94%) with no difference in total cholesterol levels. Obicetrapib was not associated with increased risk for any AE, AE leading to discontinuation, AKI, transaminase or CK elevation, and hypertension. CONCLUSION: Obicetrapib substantially improved lipid profiles in high-risk ASCVD patients on maximally tolerated lipid lowering therapy, without increased short-term adverse events. However, further long-term randomized studies are needed to confirm sustained efficacy, long-term safety, and potential impacts on clinical cardiovascular outcomes."}